Mar 10

Leukocyte-rich PRP for Knee Osteoarthritis: Current Concepts. 

Osteoarthritis is one of the most debilitating degenerative conditions affecting more than a third of the population of active individuals over the age of 65. Upon onset of clinical manifestations, osteoarthritis (OA) may become increasingly destructive regarding disease progression with respect to the microenvironment. Investigations into the leukocyte concentration in PRP formulations and its effect on the healing process in OA has created some controversy in evidence-based practice. It is well known that the inflammatory phase is integral to the...

Mar 10

Consequences on Private Insurance Coverage: The AAOS Clinical Practice Guidelines and Hyaluronic Acid Injections

Congratulations to TOBI Faculty, Dr. Vangsness and colleagues, on this important new publication in the Journal of Bone and Joint Surgery. Researchers recently reviewed the conclusions of the 2013 American Academy of Orthopedic Surgeons (AAOS) Clinical Practice Guideline (CPG) on the use of intra-articular (IA) hyaluronic acid (HA) injections and how their position has impacted private insurance coverage of these injections. The significance of such a review is warranted due to the continued high cost of hyaluronic injections as an...

Jan 14

A meta analysis does not confirm hypothesis for Platelet-Rich Plasma (PRP) versus Hyaluronic Acid (HA) in Knee Osteoarthritis

Knee Osteoarthritis is the leading cause of degenerative joint disease leading to joint dysfunction and pain. Both, intra-articular injections of PRP and HA have demonstrated effective long-term clinical management of pain symptoms and improving functionality. In 2015, as systematic review was published opposing the application of HA to treat knee osteoarthritis. Researchers Wu et al were led to hypothesize that PRP may prove to be a better modality than HA in the treatment of knee osteoarthritis, and thus performed a...